Sai Life Sciences Limited (BOM:544306)
India
· Delayed Price · Currency is INR 704.90
-0.65 (-0.09%)
At close: May 9, 2025
Sai Life Sciences Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Net Income | 828.09 | 99.89 | 62.26 | 611.01 |
| Depreciation & Amortization | 1,107 | 948.59 | 869.2 | 770.84 |
| Other Amortization | 87.67 | 45.73 | 32.41 | 24.89 |
| Loss (Gain) From Sale of Assets | -0.1 | 5.67 | -113.15 | 18.33 |
| Asset Writedown & Restructuring Costs | 61.86 | - | - | - |
| Stock-Based Compensation | 22.53 | 8.14 | 22.41 | 24.2 |
| Provision & Write-off of Bad Debts | 77.94 | 79.48 | 61.16 | 6.45 |
| Other Operating Activities | 828.61 | 657.27 | 359.87 | 190.86 |
| Change in Accounts Receivable | 288.14 | -450.79 | -432.45 | 656.73 |
| Change in Inventory | 520.87 | -126.17 | -505.64 | -323.06 |
| Change in Accounts Payable | -91.16 | 123.85 | 642.96 | -46.43 |
| Change in Other Net Operating Assets | -1,100 | 802.37 | 49.63 | -2,298 |
| Operating Cash Flow | 2,631 | 2,194 | 1,049 | -363.84 |
| Operating Cash Flow Growth | 19.91% | 109.22% | - | - |
| Capital Expenditures | -1,817 | -1,131 | -2,069 | -2,621 |
| Sale of Property, Plant & Equipment | 8.53 | 419.07 | 985.42 | 8.77 |
| Investment in Securities | 950 | -368.52 | 5 | - |
| Other Investing Activities | -1,065 | 62.39 | 41.58 | 13.03 |
| Investing Cash Flow | -1,924 | -1,018 | -1,037 | -2,599 |
| Short-Term Debt Issued | 248.93 | - | 739.39 | 1,618 |
| Long-Term Debt Issued | 750 | 300 | 1,001 | 2,188 |
| Total Debt Issued | 998.93 | 300 | 1,741 | 3,806 |
| Short-Term Debt Repaid | - | -664.36 | - | - |
| Long-Term Debt Repaid | -1,108 | -877.99 | -552.2 | -536.92 |
| Total Debt Repaid | -1,108 | -1,542 | -552.2 | -536.92 |
| Net Debt Issued (Repaid) | -109.4 | -1,242 | 1,189 | 3,269 |
| Issuance of Common Stock | 9.67 | 20.91 | 31.25 | 9.96 |
| Other Financing Activities | -853.26 | -785.04 | -500.69 | -323.65 |
| Financing Cash Flow | -952.99 | -2,006 | 719.23 | 2,955 |
| Foreign Exchange Rate Adjustments | 10.33 | 27.8 | 20.75 | - |
| Net Cash Flow | -235.6 | -802.46 | 751.5 | -7.76 |
| Free Cash Flow | 813.97 | 1,063 | -1,020 | -2,985 |
| Free Cash Flow Growth | -23.45% | - | - | - |
| Free Cash Flow Margin | 5.56% | 8.74% | -11.73% | -39.28% |
| Free Cash Flow Per Share | 4.45 | 5.83 | -5.62 | -17.31 |
| Cash Interest Paid | 853.26 | 785.04 | 500.69 | 323.65 |
| Cash Income Tax Paid | 138.73 | 40.8 | 81.23 | 154.47 |
| Levered Free Cash Flow | -254.97 | -19.44 | -2,056 | - |
| Unlevered Free Cash Flow | 281.96 | 462.16 | -1,746 | - |
| Change in Net Working Capital | 194.52 | -177.54 | 795.49 | - |
Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.